Lianwei Chuangyuan, a subsidiary of Maiwei Biotech (688062.SH), plans to introduce investors to promote the development of the innovative drug business

Zhitong Finance App News, Miwei Biotech (688062.SH) issued an announcement. According to Maiwei Biotech's strategic development plan, in order to further promote the development of the company's innovative drug business and focus on technological innovation and industrialization in the field of next-generation T-cell connectors, the company plans to sign a “capital increase agreement” and “project transfer contract” with its wholly-owned subsidiary Lianwei Chuangyuan (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “Lianwei Chuangyuan” or the “target company”). The company plans to use RMB 825 million in monetary capital to subscribe to Lianwei Chuangyuan with an additional registered capital of RMB 82.5 million and confirmed the partnership Weicron's initial registered capital of 100,000 yuan corresponds to an investment amount of RMB 1 million.

After the capital increase is completed, the registered capital of Lianwei Chuangyuan will increase from RMB 100,000 to RMB 82.6 million, and the company will still hold 100% of the shares in Lianwei Chuangyuan; the company will transfer TCE project assets, including patents, technical data and registered trademarks related to the TCE project, to Lianwei Chuangyuan at an assessed price of RMB 826 million.

In addition, the target company plans to introduce investors to sign the “Pre-A Round Capital Increase Agreement on Lianwei Chuangyuan” and the “Pre-A Shareholder Agreement on Lianwei Chuangyuan” with 5 investors. The 5 investors plan to invest a total of RMB 160 million to subscribe for Lianwei Chuangyuan with an additional registered capital of RMB 16 million, and the Shanghai Lianwei Zhihe Pharmaceutical Information Consulting Partnership (Limited Partnership) has the right to subscribe to Lianwei Chuangyuan with an additional registered capital of RMB 17.4 million after the investor's delivery is completed. After all of the above capital increases are completed, Lianwei Chuangyuan's registered capital will increase from RMB 82.6 million to RMB 116 million. The company is expected to still hold 71.21% of Lianwei Chuangyuan's shares. Lianwei Chuangyuan is a holding subsidiary within the scope of the company's consolidated statements.

The company aims to promote the development of the innovative drug business, focus on technological innovation and industrialization in the field of next-generation T-cell connectors, achieve independent accounting and specialized operation of corresponding R&D businesses, and consolidate its market-based financing foundation. This foreign investment project can strengthen the company's ability to allocate resources, broaden capital operation space, further improve R&D efficiency, and accelerate the transformation process of related technological achievements.